Fosnil 150 mg Tablets (Risedronate Sodium Dihydrate)

Adult dose

Adults: Administer 150 mg of risedronate sodium orally once a month. No dosage adjustment is necessary in elderly patients (over 60 years of age), since the bioavailability and pharmacodynamics of this medicine are similar to those in younger people. No dosage adjustment is necessary in patients with creatinine clearance of 30 mL/min or higher. This medicine is contraindicated in patients with severe renal impairment and creatinine clearance below 30 mL/min. Food interferes with the absorption of this medicine. For adequate absorption, take it at least 30 minutes before the first food or beverage other than water of the day. To allow this medicine to reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ∼ 230 mL). Taking this medicine with other beverages, including mineral water, may reduce its absorption. Do not chew or suck this medicine because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. If a patient forgets to take a dose on the scheduled day, follow these instructions. If the next scheduled dose is 7 days or more away, take 1 tablet the next morning after remembering. Resume the next dose on the originally scheduled day. Do not take more than 1 tablet of this medicine within 7 days. If the next scheduled dose is within 7 days, wait until the originally scheduled day and then take 1 tablet of this medicine.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

This medication can irritate the gastric and esophageal mucosa, so patients with upper gastrointestinal diseases such as gastritis, esophagitis, or ulcers need to take caution when using it. Always take it with enough water and refrain from lying down for at least 30 minutes after taking it to help reduce esophageal irritation. If you experience difficulty swallowing, chest pain, or heartburn, stop taking the medication immediately and consult a doctor. Patients with esophageal motility disorders, hypocalcemia, women who are pregnant or breastfeeding, and those with severe renal impairment should not take this medication. As a bisphosphonate, long-term use may rarely lead to serious side effects such as osteonecrosis of the jaw and atypical fractures; therefore, regular check-ups and caution are necessary. Taking this medication with foods or drugs that contain calcium, magnesium, iron, or aluminum may interfere with its absorption, so maintain an adequate time interval between dosages. This medication may affect the fetus during pregnancy; therefore, women of childbearing potential should consult a doctor before taking it, and caution is also necessary for breastfeeding women. Safety and efficacy in pediatric patients have not been established, so children under 18 years of age should avoid its use. Elderly individuals show similar safety and efficacy to adults, but caution is advisable based on individual health status. In case of overdose, serum calcium and phosphorus levels may decrease, so immediate medical attention is necessary. This medication should be kept out of reach of children, and transferring it to another container is not advisable for quality and safety maintenance.

• esophagitis
• esophageal ulcer
• esophageal erosion
• esophageal obstruction
• esophageal perforation
• bleeding
• infection
• back pain
• accidental injury
• pain

This medication should be stored in a tightly sealed container to prevent exposure to air, and it is important to maintain the storage temperature between 1 degree and 30 degrees Celsius. Proper storage will help preserve the drug's effectiveness over time.

Appearance

Bright blue oblong film-coated tablet

Package unit

1 tablet/PTP